Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.

Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D

Pediatric obesity13 Apr 2016Cited by 58 (Europe PMC)

PMID27071367PMCIDPMC5288290DOI10.1111/ijpo.12131PepBankPUB-27071367

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, exenatide significantly reduced appetite scores from baseline at 1, 3 and 6 months.
In plain wordsIn youth with Prader-Willi syndrome, appetite scores decreased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAppetite scores
Study
n = 10
Comparator
baseline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Measurements
Appetite score
32.2 points
baseline
Appetite score
27.5 points
1 month
Appetite score
25.4 points
3 months
Appetite score
25.4 points
6 months
Source sentences
Summary
Appetite scores significantly decreased from baseline (32.2 ± 8.7) after 1, 3 and 6 moths of treatment (27.5 ± 8.8, 25.4 ± 9.3, and 25.4 ± 7.2 respectively; p = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136701
02HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, hemoglobin A1c significantly decreased from baseline after exenatide treatment.
In plain wordsIn youth with Prader-Willi syndrome, HbA1c decreased from baseline after exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHemoglobin A1c
Study
n = 10
Comparator
baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136702
03HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, exenatide did not significantly change weight from baseline.
In plain wordsIn youth with Prader-Willi syndrome, weight did not change significantly from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n = 10
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136703
04HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, exenatide did not significantly change BMI z-score from baseline.
In plain wordsIn youth with Prader-Willi syndrome, BMI z-score did not change significantly from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI z-score
Study
n = 10
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136704
05HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, exenatide did not significantly change adiposity from baseline.
In plain wordsIn youth with Prader-Willi syndrome, body fat did not change significantly from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdiposity
Study
n = 10
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Source sentences
Summary
Hemoglobin A1c decreased significantly after treatment, but weight, BMI z-score and adiposity did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136705
06HumanNon-randomized trialEfficacy outcome
In overweight youth with Prader-Willi syndrome, exenatide did not significantly change ghrelin from baseline.
In plain wordsIn youth with Prader-Willi syndrome, ghrelin did not change significantly from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGhrelin
Study
n = 10
Comparator
baseline
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
standard diabetes dosing · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant change in ghrelin.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten overweight and obese subjects with PWS (13-25 years) were recruited for a 6-month open-label, non-randomized, longitudinal study conducted at Children's Hospital Los Angeles.
Summary · context
Exenatide was given using standard diabetes dosing without dietary modifications.
Report a problemFND-2707136706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01444898

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Children's Hospital Los Angelesn = 10Mar 2012 to Dec 2013

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 29 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.